touchRESPIRATORY joins Professor Frédéric de Blay (University Hospital of Strasbourg, Strasbourg, France) at EAACI 2021 to discuss the results of a phase 2, randomised, double-blind, placebo-controlled study of anti-Fel d 1 monoclonal antibodies in reducing the rate of early asthma responses, chest symptoms and rescue medication use in cat-allergic subjects with mild asthma for up to 3 months following a controlled cat allergen challenge.
Questions
1. Could you give us a brief overview of the health burden of cat allergy? (00:29-01:57)
2. What are anti-Fel d 1 monoclonal antibodies and what is the rationale for use in combating cat allergy? (01:57 -02:43)
3. What were the aims and design of the Phase 2 study? (02:43-04:00)
4. What were the efficacy and safety findings of the study? (04:00-05:00)
5. What will be the next step in the clinical development of anti-Fel d 1 monoclonal antibodies? (05:00-06:04)
Disclosures: Professor Frédéric de Blay has no financial or non-financial conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Sophie Nickelson.
Filmed in coverage of the 2021 EAACI Annual Meeting.
